Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

By W. Abraham, P. Adamson, R. Bourge, M. Aaron, M. Costanzo, L. Stevenson, Warren Strickland, Suresh Neelagaru, N. Raval, S. Krueger and 4 more. The Lancet, 2011

1,560 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/a840424043ee1814e2b99bed302956bf190d89f8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. T. Horwich
3. J. Januzzi
4. C. Yancy
5. M. Drazner
6. Véronique L. Roger
7. M. Gheorghiade

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “Diagnosis or exclusion of HF Acute I A (212, 217-223, 245-250)”
• Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, background): “Clinical studies to investigate innovative monitoring and management techniques (serial biomarkers, bioimpedance, chronic in vivo monitoring.(212) Evaluate effects of CHF-specific risk-modifying and cardio-protective therapies (ACEIs, ARBs, renin and mineralocorticoid hormone inhibitors.”
• Definitions and diagnosis of pulmonary hypertension. (2013, background): “In many patients with left heart disease, it will be possible to at least temporarily lower PAWP below 15 mm Hg with meticulous afterload reduction and diuretic medication (15).”
• Rehospitalization for heart failure: problems and perspectives. (2013, neutral): “Age, yrs 69 [59–77]”